Conv. Plasma
Nigella Sativa

All regdanvimab studies
Meta analysis
study COVID-19 treatment researchRegdanvimabRegdanvimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Progression, all 51% Improvement Relative Risk Progression, delta 34% Oxygen therapy, all 32% Oxygen therapy, delta 4% Regdanvimab for COVID-19  Kim et al.  EARLY TREATMENT Is early treatment with regdanvimab beneficial for COVID-19? Retrospective 2,214 patients in South Korea (Dec 2020 - Sep 2021) Lower progression (p=0.00018) and lower oxygen therapy (p<0.0001) Kim et al., Frontiers in Cellular and .., May 2023 Favors regdanvimab Favors control

Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study

Kim et al., Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2023.1192512
May 2023  
  Source   PDF   All   Meta
35th treatment shown to reduce risk in March 2022
*, now known with p = 0.0000009 from 7 studies, recognized in 27 countries. Efficacy is variant dependent.
Lower risk for hospitalization, progression, and recovery.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 2,214 mild/moderate COVID-19 patients in South Korea, 1,095 treated with regdanivimab, showing lower oxygen requirements and lower progression to severe disease with treatment in the overall cohort, but not within the delta subset.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2, BA.4, BA.5 Haars, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1 Pochtovyi.
risk of progression, 51.1% lower, HR 0.49, p < 0.001, treatment 1,095, control 1,119, adjusted per study, all, multivariable.
risk of progression, 33.5% lower, HR 0.67, p = 0.22, treatment 1,095, control 1,119, adjusted per study, delta, multivariable.
risk of oxygen therapy, 32.3% lower, HR 0.68, p < 0.001, treatment 1,095, control 1,119, adjusted per study, all, multivariable.
risk of oxygen therapy, 3.7% lower, HR 0.96, p = 0.83, treatment 1,095, control 1,119, adjusted per study, delta, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kim et al., 15 May 2023, retrospective, South Korea, peer-reviewed, 20 authors, study period December 2020 - September 2021. Contact:,,,
This PaperRegdanvimabAll
Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study
Haein Kim, Young Rock Jang, Ji Yeon Lee, Jae-Hoon Ko, Jee Young Lee, Seongcheol Cho, Yong Dae Lee, Junghoon Song, Miri Hyun, Hyun Ah Kim, Soyoon Hwang, Sangmi Ryou, Yoo Jin Na, Joo-Yeon Lee, Changhee Lee, Nan Young Lee, Seunghwan Shin, Ki Tae Kwon, Jin Yong Kim, Kyong Ran Peck
Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2023.1192512
Background: Immune-evading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are emerging continuously. The clinical effectiveness of monoclonal antibody agents that exhibit decreased in vitro activity against SARS-CoV-2 variants needs to be elucidated. Methods: A nationwide, multicenter, retrospective cohort study was designed to evaluate the effectiveness of regdanvimab, an anti-SARS-CoV-2 monoclonal antibody agent. Regdanvimab was prescribed in South Korea before and after the emergence of the delta variant, against which the in vitro activity of regdanvimab was decreased but present. Mild to moderate coronavirus 2019 (COVID-19) patients with risk factors for disease progression who were admitted within seven days of symptom onset were screened in four designated hospitals between December 2020 and September 2021. The primary outcomes, O 2 requirements and progression to severe disease within 21 days of admission, were compared between the regdanvimab and supportive care groups, with a subgroup analysis of delta variant-confirmed patients. Results: A total of 2,214 mild to moderate COVID-19 patients were included, of whom 1,095 (49.5%) received regdanvimab treatment. In the analysis of the total Frontiers in Cellular and Infection Microbiology 01
Ethics statement Review by the Institutional Review Board was exempted because the present investigation was conducted as part of a public health response, and minimal risk was expected to the participating patients. Author contributions HK, YRJ, JYL, and J-HK have contributed equally to this work and share first authorship. SS, KTK, JYK, and KRP have contributed equally to this work and share corresponding authorship. All authors contributed to the article and approved the submitted version. Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Supplementary material The Supplementary Material for this article can be found online at: full#supplementary-material
Bae, Ko, Choi, Park, Lim et al., Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity, Clin. Microbiol. Infect, doi:10.1016/j.cmi.2022.04.019
Bierle, Ganesh, Razonable, Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1. 617.2 (Delta) surge, J. Clin. Virol, doi:10.1016/j.jcv.2021.105026
Cox, Peacock, Harvey, Hughes, Wright et al., SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies, Nat. Rev. Microbiol, doi:10.1056/NEJMoa2102685
Gottlieb, Nirula, Chen, Boscia, Heller et al., Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, Jama, doi:10.1001/jama.2021.0202
Gupta, Gonzalez-Rojas, Juarez, Crespo Casal, Moya et al., Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial, Jama, doi:10.1001/jama.2022.2832
Jang, Oh, Kim, Regdanvimab for patients with mild-tomoderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the delta variant, Int. J. Infect. Dis, doi:10.1016/j.ijid.2022.12.035
Joo, Ko, Kim, Kang, Baek et al., Clinical and virologic effectiveness of remdesivir treatment for severe coronavirus disease 2019 (COVID-19) in Korea: a nationwide multicenter retrospective cohort study, J. Korean Med. Sci, doi:10.3346/jkms.2021.36.e83
Kim, Lee, Kim, Kim, Kim et al., COVID-19 special report] July 2021 status and characteristics of the COVID-19 variant virus outbreak in the republic of Korea
Kim, Ryu, Lee, Kim, Seo et al., A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein, Nat. Commun, doi:10.1038/s41467-020-20602-5
Lee, Lee, Ko, Hyun, Kim et al., Effectiveness of regdanvimab treatment in high-risk COVID-19 patients to prevent progression to severe disease, Front. Immunol, doi:10.3389/fimmu.2021.772320
Lee, Lee, Lee, Kim, Lee et al., Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: a propensity score-matched retrospective cohort study, Int. Immunopharmacol, doi:10.1016/j.intimp.2022.108570
Lee, Park, Lee, Early oxygen requirement in patients with mild-to-Moderate COVID-19 who received regdanvimab after delta-variant outbreak, Infect. Chemother, doi:10.3947/ic.2022.0011
Mayo, Error statistics, Philosophy of statistics
Nham, Ko, Song, Choi, Kim et al., Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the delta variant: a prospective nationwide cohort study comparing three COVID-19 vaccination protocols in south Korea, Front. Immunol, doi:10.3389/fimmu.2022.968105
Nham, Song, Noh, Cheong, Kim, National Institutes of Health. COVID-19 treatment guidelines, anti-SARS-CoV-2 monoclonal antibodies, J. Korean Med. Sci, doi:10.3346/jkms.2022.37.e351
Park, Lim, Kim, Park, Lim et al., Clinical and virological characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV
Planas, Veyer, Baidaliuk, Staropoli, Guivel-Benhassine et al., Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization, Nature, doi:10.1038/s41586-021-03777-9
Ryu, Kang, Noh, Woo, Lee et al., The in vitro and in vivo efficacy of CT-P59 against gamma, delta and its associated variants of SARS-CoV-2, Biochem. Biophys. Res. Commun, doi:10.1016/j.bbrc.2021.09.023
Salleh, Derrick, Deris, Structural evaluation of the spike glycoprotein variants on SARS-CoV-2 transmission and immune evasion, Int. J. Mol. Sci, doi:10.3390/ijms22147425
Streinu-Cercel, Sandulescu, Preotescu, Kim, Kim et al., Efficacy and safety of regdanvimab (CT-P59): a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-Moderate coronavirus disease, Open Forum Infect. Dis, doi:10.1093/ofid/ofac053
Sung, Kim, Heo, Seo, Jang et al., Clinical course and outcomes of 3,060 patients with coronavirus disease 2019 in Korea, J. Korean Med. Sci, doi:10.3346/jkms.2020.35.e280
Syed, Regdanvimab: first approval, Drugs, doi:10.1007/s40265-021-01626-7
Takashita, Kinoshita, Yamayoshi, Sakai-Tagawa, Fujisaki et al., Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA
Twohig, Nyberg, Zaidi, Thelwall, Sinnathamby et al., Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study, Lancet Infect. Dis, doi:10.1016/S1473-3099(21)00475-8
Vanblargan, Errico, Halfmann, Zost, Crowe et al., None
Wen, Badgett, Cornell, Number needed to treat: a descriptor for weighing therapeutic options, Am. J. Health Syst. Pharm, doi:10.2146/ajhp040558
Yamasoba, Kosugi, Kimura, Fujita, Uriu et al., Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies, Lancet Infect. Dis, doi:10.1016/S1473-3099(22)00365-6
Yang, Won, Baek, Lee, Kim et al., Neutralizing activity against omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after omicron BA.1/BA.2 breakthrough infections, Front. Immunol, doi:10.3389/fimmu.2023.1139980
Zhou, Wang, Misasi, Pegu, Zhang et al., Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529, Science, doi:10.1126/science.abn8897
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop